← Leaderboards
Paul Dent
Virginia Commonwealth University
$11,860,656
Attributed
$11,860,656
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $935.6K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,860,656 · 9
By mechanism
R01$10,048,356 · 6
P01$1,413,113 · 2
R21$399,187 · 1
Top collaborators
No co-investigators on record.
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Anindita Das$3,017,498
- Gordon D Ginder$21,192,432
- Hisashi Harada$3,277,011
- Timothy B Langston$288,302
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroCellsToxic EffectInhibitor/AntagonistBasePharmaceutical PreparationsNeoplastic CellCell KillingKillingsIn VivoTumorApoptosisMitochondriaTumor GrowthMolecularResistanceAutophagocytosisPhosphotransferasesCell TypeCell DeathPathway InteractionsCell SurvivalSignal TransductionIonizing Radiation
Grant awards (45)
ATG16L1 isoforms and CRC health disparities$399,187
R21 · FY2024 · CA · contact PI
Pemetrexed and sildenafil for lung cancer$304,539
R01 · FY2019 · CA · contact PI
Pemetrexed and sildenafil for lung cancer$313,959
R01 · FY2018 · CA · contact PI
Pemetrexed and sildenafil for lung cancer$313,959
R01 · FY2017 · CA · contact PI
Pemetrexed and sildenafil for lung cancer$313,959
R01 · FY2016 · CA · contact PI
Pemetrexed and sildenafil for lung cancer$313,959
R01 · FY2015 · CA · contact PI
Lapatinib and Obatoclax combination therapy$328,364
R01 · FY2014 · CA · contact PI
OSU-03012 therapy for glioblastoma$292,282
R01 · FY2014 · CA · contact PI
Lapatinib and Obatoclax combination therapy$318,209
R01 · FY2013 · CA · contact PI
OSU-03012 therapy for glioblastoma$283,242
R01 · FY2013 · CA · contact PI
Signaling Pathways Regulating Epithelial Cell Survival$276,784
R01 · FY2013 · DK · contact PI
Lapatinib and Obatoclax combination therapy$338,520
R01 · FY2012 · CA · contact PI
OSU-03012 therapy for glioblastoma$301,321
R01 · FY2012 · CA · contact PI
Signaling Pathways Regulating Epithelial Cell Survival$286,823
R01 · FY2012 · DK · contact PI
Lapatinib and Obatoclax combination therapy$338,520
R01 · FY2011 · CA · contact PI
OSU-03012 therapy for glioblastoma$310,210
R01 · FY2011 · CA · contact PI
Signaling Pathways Regulating Epithelial Cell Survival$286,823
R01 · FY2011 · DK · contact PI
OSU-03012 therapy for glioblastoma$321,410
R01 · FY2010 · CA · contact PI
Signaling Pathways Regulating Epithelial Cell Survival$319,691
R01 · FY2010 · DK · contact PI
Lapatinib and Obatoclax combination therapy$155,106
R01 · FY2010 · CA · contact PI
MDA-7/IL-24: Therapy of Malignant Glioma$299,856
P01 · FY2009 · CA · contact PI
Signaling Pathways Regulating Epithelial Cell Survival$287,040
R01 · FY2009 · DK · contact PI
MDA-7/IL-24 and free radicals in renal cancer therapy$279,026
R01 · FY2009 · CA · contact PI
MDA-7/IL-24: Therapy of Malignant Glioma$294,179
P01 · FY2008 · CA · contact PI
MDA-7/IL-24 and free radicals in renal cancer therapy$279,026
R01 · FY2008 · CA · contact PI
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL SURVIVAL$209,073
R01 · FY2008 · DK · contact PI
MDA-7/IL-24: Therapy of Malignant Glioma$320,989
P01 · FY2007 · CA · contact PI
MDA-7/IL-24 and free radicals in renal cancer therapy$279,026
R01 · FY2007 · CA · contact PI
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL SURVIVAL$213,341
R01 · FY2007 · DK · contact PI
MDA-7/IL-24 and free radicals in renal cancer therapy$287,360
R01 · FY2006 · CA · contact PI
MDA-7/IL-24: Therapy of Malignant Glioma$252,519
P01 · FY2006 · CA · contact PI
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL SURVIVAL$219,713
R01 · FY2006 · DK · contact PI
MDA-7/IL-24 and free radicals in renal cancer therapy$294,275
R01 · FY2005 · CA
MDA-7/IL-24: Therapy of Malignant Glioma$245,570
P01 · FY2005 · CA
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL SURVIVAL$225,000
R01 · FY2005 · DK
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL SURVIVAL$225,000
R01 · FY2004 · DK
Carcinoma cell radiosensitization by MAPK inhibition$195,750
R01 · FY2004 · CA
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL GROWTH$195,841
R01 · FY2003 · DK
Carcinoma cell radiosensitization by MAPK inhibition$195,750
R01 · FY2003 · CA
Carcinoma cell radiosensitization by MAPK inhibition$195,750
R01 · FY2002 · CA
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL GROWTH$190,137
R01 · FY2002 · DK
BILE ACID SIGNALING AND HEPATIC CHOLESTOROL METABOLISM$0
P01 · FY2002 · DK
Carcinoma cell radiosensitization by MAPK inhibition$195,750
R01 · FY2001 · CA
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL GROWTH$184,598
R01 · FY2001 · DK
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL GROWTH$179,220
R01 · FY2000 · DK